Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

By sjmartinez • January 14, 2025

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025.01.001. Epub ahead of print. PMID: 39805351.

Tags: Advanced NSCLC, antibody-drug conjugate, c-Met, Hematology/Oncology, Osimertinib, Publications, Teliso-V

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.[...]

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, Di Pace B, Wang T, Zhang H, Ghosh S, Yanamandra N, Borgovan T,[...]

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study

Gupta M, Schoettler ML, Orozco G, Brazauskas R, Bo-Subait S, Battiwalla M, Buchbinder D, Hamilton BK, Savani BN, Schoemans H, Sorror ML, Ahmed S, Badawy[...]